eLearning Liver MRI
Presenters: Elmar M. Merkle, Matthias R. Benz, Christoph J. Zech, Daniel T. Boll from the University of Basel, Switzerland
Presenters: Elmar M. Merkle, Matthias R. Benz, Christoph J. Zech, Daniel T. Boll from the University of Basel, Switzerland
Applications of liver MRI and the Role of Primovist® Enhancement
Primovist® – or gadoxetic acid – is a gadolinium-based contrast agent indicated for liver MRI. Primovist®-enhanced MRI has gained an important place in clinical practice and changed the way that liver imaging is performed, as a consequence of its unique imaging characteristics and clinical applications.
This webinar, presented by experts from the University of Basel, consists of an introduction and four parts that describe the applications of liver MRI and the role of Primovist® enhancement:
eLearning Liver MRI 01
PART 1
Value of Different Modalities
Presenter: Matthias R. Benz, Clinic of Radiology and Nuclear Medicine, Basel.
Duration: 25:37 min
eLearning Liver MRI 03
PART 3
Use of Hepatobiliary MRI in the Setting of Patients WITH Liver Cirrhosis
Presenter: Daniel T. Boll, University of Basel.
Duration: 19:13 min
eLearning Liver MRI 02
PART 2
Gadoxetic Acid – Product Characteristics and Mode of Action.
Presenter: Christoph J. Zech, University of Basel.
Duration: 31:12 min
eLearning Liver MRI 04
PART 4
Use of Hepatobiliary MRI in the Setting of Patients WITHOUT Liver Cirrhosis
Presenter: Christoph J. Zech, University of Basel.
Duration: 39:12 min
eLearning Liver MRI 01
PART 1
Value of Different Modalities
Presenter: Matthias R. Benz, Clinic of Radiology and Nuclear Medicine, Basel.
Duration: 25:37 min
eLearning Liver MRI 02
PART 2
Gadoxetic Acid – Product Characteristics and Mode of Action.
Presenter: Christoph J. Zech, University of Basel.
Duration: 31:12 min
eLearning Liver MRI 03
PART 3
Use of Hepatobiliary MRI in the Setting of Patients WITH Liver Cirrhosis
Presenter: Daniel T. Boll, University of Basel.
Duration: 19:13 min
eLearning Liver MRI 04
PART 4
Use of Hepatobiliary MRI in the Setting of Patients WITHOUT Liver Cirrhosis
Presenter: Christoph J. Zech, University of Basel.
Duration: 39:12 min
.
Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6(3):244-51.
Bohte AE et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21(1):87-97.
Boll DT, Merkle EM. Diffuse liver disease: strategies for hepatic CT and MR imaging. RadioGraphics. 2009;29(6):1591-614
Choi JS et al. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol. 2010;20(5):1052-60.
Dalrymple NC. Problem Solving in Abdominal Imaging. Elsevier, 1st edition 2009. ISBN: 9780323043533.
Ernst O et al. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol. 1997;168(5):1205-8.
Gandon Y et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363(9406):357-62.
Gonzalez-Guindalini FD et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics. 2013; 33(6):1781-800.
St Pierre TG et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-61.
Torres DM et al. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10(8):837-58.
Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901-10.
Website:
.
Bashir MR, Merkle EM. Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol. 2011;21(2):291-4.
Choi JS et al. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol. 2010;20(5):1052-60.
Kim YK et al. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxetic acid. JMRI. 2009;30(2):437-43.
Lauenstein T et al. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol. 2015;50(6):416-22.
Rohrer M et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715-24.
Saito K et al. Effect of Gd-EOB-DTPA on T2-weighted and diffusion-weighted images for the diagnosis of hepatocellular carcinoma. JMRI. 2010;32(1):229–34.
Schmid-Tannwald C, Zech CJ, et al. Presentation at ESMRMB, 2009.
Van der Borght S et al. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol. 2005;207(4):471-82.
Zech CJ et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44(6):305-10.
Website:
.
Choi JY et al. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635-54.
Choi J, et al. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273(1):30-50.
Forner A et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47(1):97-104.
Ishigami K et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology. 2009;250(2):435-43.
Katyal S et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216(3):698-703.
Sneag DB et al. Extrahepatic spread of hepatocellular carcinoma: spectrum of imaging findings. AJR Am J Roentgenol. 2011;197(4):W658-64.
.
Bashir MR et al. Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? JMRI. 2012;35(3):611-6.
Bioulac-Sage P et al. Hepatocellular adenoma: what is new in 2008. Hepatol Int. 2008;2(3):316-21.
Grazioli L et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology. 2012;262(2):520-9
Yoshimitsu K et al. Unusual hemodynamics and pseudolesions of the noncirrhotic liver at CT. Radiographics. 2001;21(Suppl 1):S81-96.
Zech CJ et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43(7):504-11.
Zech CJ et al. Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: results from the VALUE Trial. Eur Radiol. 2016;26(11):4121-30.
